Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption;Repercusión cardiovascular, con y sin alcohol, del carbonato de lodenafila, un nuevo inhibidor de la PDE5

Arquivos Brasileiros de Cardiologia

Volumn 94, Issue 2, 2010, Pages

  Silva, Adauto Carvalho ^a   Toffoletto, Odaly ^b   Lucio, Luiz Antonio Galvão ^c   Dos Santos, Paula Ferreira ^a   Afiune, Jorge Barros ^c   Filho, João Massud ^b   Tufik, Sergio ^a  

^a Unidade de Farmacocinética Biocrom   (Brazil)

^b Newco Trials Pesquisa Científica Ltda   (Brazil)

^c Cristalia Produtos Quimicos e Farmacêuticos Ltda   (Brazil)

Author keywords

Alcohol drinking; Attributable risk; Cardiovascular system; Erectile dysfunction; Phosphodiesterase inhibitors

Indexed keywords

ALCOHOL; LODENAFIL CARBONATE; PHOSPHODIESTERASE V INHIBITOR; UNCLASSIFIED DRUG; BIS (2 (4 (4 ETHOXY 3 (1 METHYL 7 OXO 3 PROPYL 6,7 DIHYDRO 1H PYRAZOLO(4,3 D)PYRIMIDIN 5 YL) BENZENESULFONYL)PIPERAZIN 1 YL) ETHYL)CARBONATE; BIS-(2-(4-(4-ETHOXY-3-(1-METHYL-7-OXO-3-PROPYL-6,7-DIHYDRO-1H-PYRAZOLO(4,3-D)PYRIMIDIN-5-YL)-BENZENESULFONYL)PIPERAZIN-1-YL)-ETHYL)CARBONATE; CARBONIC ACID DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ALCOHOL CONSUMPTION; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SAFETY; HEADACHE; HEART RATE; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; ADOLESCENT; ANALYSIS OF VARIANCE; BIOAVAILABILITY; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DRINKING BEHAVIOR; DRUG EFFECT; HEART MUSCLE CONDUCTION SYSTEM; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; ALCOHOL DRINKING; ANALYSIS OF VARIANCE; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; CARBONATES; CARDIOVASCULAR SYSTEM; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PYRIMIDINES; YOUNG ADULT;

EID: 77951989040     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med. 1998; 338: 1397-1404
2. Spark RF, White RA, Connolly PB. Impotence is not always psychogenic: hypothalzamic-pituitary gonadal sysfunction. JAMA. 1980; 243: 750-755
3. Stein R, Hohmann CB. Atividade sexual e coração. Arq Bras Cardiol. 2006; 86: 61-67
4. Feldman HA, Goldstein I, Hatsziehristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Agins Study. J Urol. 1994; 151 (1): 54-61.
5. Albuquerque DC, Miziara LJ, Saraiva JFK, Rodrigues US, Ribeiro AB, Wajngarten M. Efficacy, safety and tolerability of sildenafil in brazilian hypertensive patients on multiple antihypertensive drugs. Int Braz J Urol. 2005; 31: 342-355 (Pubitemid 41288442)
6. Sussman DO. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. J Am Osteopath Assoc. 2004; 3 (Suppl 4): s11-s15.
7. De Nucci, G, Lorenzetti R, Okuyama CE, Baracat JS, Donato JL, Antunes E, et al. Pharmacological characterization of the novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. BMC Pharmacology. 2007, 7 (Suppl 1): P13.
8. Zincaglia LCM, De Angelis K, Taricanos ID, Pagani E. Toxicidade oral aguda do carbonato de lodenafila em camundongos. Int Braz J Urol. 2007; 33 (Suppl 2): 140.
9. Taricano ID, Zicaglia LCM, Nicolau AA, Pagani E. Toxicidade oral aguda do carbonato de lodenafila em cães. Int Braz J Urol. 2007; 33 (Suppl 2): 143.
10. Taricano ID, De Angelis K, Bonamin LV, Zincaglia LCM, Pagani E. Avaliação histopatológica de órgão reprodutivo masculino após administraçãode carbonato de lodenafila a ratos. Int Braz J Urol. 2007; 33 (Suppl 2): 51.
11. Zincaglia LCM, Taricano ID, De angelis K, Bonamin LV, Pagani E. Toxicidade doses repetidas para carbonato de lodenafila em rato. Int Braz J Urol. 2007; 33 (Suppl 2): 136.
12. Lucio LA, Pagani E, Afiune JB. Carbonato de lodenafila no tratamento da disfunção erétil. RBM Rev Bras Med. 2007; 64 (9): 425-432
13. De Nucci. Estudo clínico fase I do carbonato de lodenafila em voluntários sadios do sexo masculino. Int Braz J Urol. 2007; 33 (Suppl 2): 148.
14. Toffoletto O, Santos PF, Ribeiro AB, Massud J, Afiune J, Pagani E. Farmacocinética do carbonato de lodenafila: proporcionalidadede dose. Int Braz J Urol. 2007; 33 (Suppl 2): 148.
15. Glina S, Gromatzky C, Nardozza A, Afiune JB, Pagani E. Estudo clínico fase II de eficácia e tolerabilidade do carbonato de lodenafila para tratamento de disfunção erétil. Int Braz J Urol. 2007; 33 (Suppl 2): 320.
16. Fonseca GN, Damião R, Bertero EB, Rocha LCA, Jardin CRF, Pagani E. Estudo clínico fase III de eficácia e tolerabilidade do carbonatode lodenafila para tratamento de disfunção erétil. Int Braz J Urol. 2007; 33 (Suppl 2): 148.
17. Galduróz JCF, Caetano R. Epidemiologia do uso de álcool no Brasil. Rev Bras Psiquiatr. 2004; 26 (supl.1): 3-6.
18. Sehested J, Heringlake M, Schmidt V. Neurohumoral cardiovascular responses to alcohol and their modulation by peroral fluid. Am J Cardiol. 1998; 81: 761-765 (Pubitemid 28146453)
19. Hashimoto M, Kim S, Eto M, Iijima K, Ako J, Yoshizumi M, et al. Effect of acute intake of red wine on flow-mediated vasodilatation of the brachial artery. Am J Cardiol. 2001; 88: 1457-1460 (Pubitemid 34008701)
20. Venkov CD, Myers PR, Tanner MA, Su M, Vaughan DE. Ethanol increases endothelial nitric oxide production through modulation of nitric oxide synthase expression. Thromb Haemost. 1999; 81: 638-642 (Pubitemid 29178955)
21. Acevado CG, Carrasco G, Burotto M, Rojas S, Bravo I. Ethanol inhibits L-arginine uptake and enhances NO formation in human placenta. Life Sci. 2001; 68: 2893-2903 (Pubitemid 32453257)
22. Abe H, Kawano Y, Kojima S, Ashida T, Kuramochi M, Matsuoka H, et al. Biphasic effects of repeated alcohol intake on 24-hour blood pressure in hypertensive patients. Circulation. 1994; 89: 2626-2633 (Pubitemid 24173680)
23. Johnson RH, Eisenhofer G, Lambie DG. The effects of acute and chronic ingestion of ethanol on the autonomic nervous system. Drug Alcohol Depend. 1986; 18: 319-328 (Pubitemid 17213875)
24. Scivoletto S, Tsuji RK, Abdo CH, Queiroz S, Andrade AG, Gattaz WF. Relação entre consumo de drogas e comportamento sexual de estudantes de 2o grau de São Paulo. Rev Bras Psiquiatr. 1999; 21 (2): 87-94.
25. Carson CC 3rd. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol. 2005; 96 (12B): 37M-41M.
26. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation. 2004; 110 (19): 3149-3155 (Pubitemid 39492012)
27. Guimarães AC, Malachias MV, Coelho OR, Zilli EC, Luna RL. Uso do sildenafil em pacientes com doença cardiovascular. Arq Bras Cardiol. 1999; 73 (6): 515-526
28. Leslie SJ, Atkins G, Oliver JJ, Webb DJ. No adverse hemodynamic interaction between sildenafil and red wine. Clin Pharmacol Ther. 2004; 76: 265-270 (Pubitemid 39313127)
29. Wensing G, Bauer R, Unger S, Rohde G, Heinig R. Simultaneous administration of vardenafil and alcohol does not result in a pharmacodynamic or pharmacokinetic interaction in health male subjects. Int J Clin Pharmacol Ther. 2006; 44: 216-224 (Pubitemid 43676440)
30. Mitchell M, Sanderson B, Payne C, Bedding A. Pharmacodynamic interaction between alcohol and tadalafil in healthy volunteers. Int J Impot Res. 2002; 14 (Suppl 4): S64 P-112.
31. Lorsheyd A, de Lange DW, Hijmering ML, Cramer MJ, van de Wiel A. PR and OTc interval prolongation on the electrocardiogram after binge drinking in healthy individuals. Neth J Med. 2005; 63 (2): 59-63. (Pubitemid 40347735)